Arbutus Biopharma
ABUS
ABUS
112 hedge funds and large institutions have $119M invested in Arbutus Biopharma in 2022 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 40 increasing their positions, 37 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
5% less funds holding
Funds holding: 118 → 112 (-6)
9% less capital invested
Capital invested by funds: $131M → $119M (-$11.5M)
26% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 19
Holders
112
Holding in Top 10
2
Calls
$4.81M
Puts
$2.63M
Top Buyers
| 1 | +$5.81M | |
| 2 | +$3.53M | |
| 3 | +$1.94M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.26M |
| 5 |
FCM
FourWorld Capital Management
New York
|
+$686K |
Top Sellers
| 1 | -$3.46M | |
| 2 | -$2.2M | |
| 3 | -$1.15M | |
| 4 |
BC
Brookfield Corp
Toronto,
Ontario, Canada
|
-$1.12M |
| 5 |
Barclays
London,
United Kingdom
|
-$912K |